Financial Health Snapshot
What do Eli Lilly and Company’s latest financial health metrics show?
Strong. Revenue and EPS momentum are the clearest strengths, backed by Q1 2026 growth and full-year 2026 revenue guidance. The main concern is pricing pressure, plus incomplete balance-sheet and cash-flow visibility.
This snapshot uses Q1 2026, ended 2026-03-31. The verdict combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency, so Eli Lilly and Company looks financially strong even though the cash-flow and leverage picture is less complete than the income statement. For investor context, see Exploring Eli Lilly and Company (LLY) Investor Profile: Who's Buying and Why?.
Revenue deserves deeper analysis first because it best shows whether demand can sustain the $8200B–$8500B full-year 2026 outlook, while the $740B net income and $826 EPS figures confirm profit momentum.
Revenue Quality
Is Eli Lilly and Company’s revenue growth producing quality earnings?
Strong. Eli Lilly and Company’s $1980B revenue growth and the matching net income and EPS gains point to earnings-backed growth, not just sales volume. The clearest caution is pricing pressure, which keeps the quality picture from being flawless.
Eli Lilly and Company’s growth looks strong in quantity and quality because higher prescription demand is showing up in operating results, not just top-line sales. Investors compare revenue durability with operating income, net income, and EPS across compatible annual periods to see whether growth converts into real profit. For background, see Eli Lilly and Company (LLY): History, Ownership, Mission, How It Works & Makes Money.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $1980B, 56% growth, Q1 2026 | Unavailable in the supplied data | Prescription-demand driven, especially tirzepatide franchises | The growth source looks repeatable, but pricing pressure still matters |
| Operating Income | Unavailable in the supplied data | Unavailable in the supplied data | Unable to verify the pace versus revenue | Operating leverage cannot be confirmed from the supplied figures |
| Net Income | Company-reported Q1 2026 net income growth: 168% | Unavailable in the supplied data | Earnings rose faster than revenue, supported by demand | Final earnings confirm the operating strength implied by sales |
| Diluted EPS | Company-reported Q1 2026 EPS growth: 170% | Unavailable in the supplied data | Per-share gains tracked profit growth closely | Shareholders saw the growth show up in per-share results |
How durable is Eli Lilly and Company’s revenue?
Durability looks solid, led by recurring prescription demand, but the biggest limitation is pricing pressure from government and commercial agreements, which can cap realized revenue even when volumes stay strong.
- Demand Quality: Repeat prescription demand supports visibility, and updated full-year 2026 revenue guidance of $8200B–$8500B adds more clarity.
- Pricing and Volume: US realized price change was -7%, while US volume growth for Zepbound was 80%; the split is clear enough to show volume offsetting price pressure.
- Diversification: Mounjaro revenue of $866B, Zepbound revenue of $416B, and Verzenio revenue of $160B help, but the business still has concentration in the tirzepatide franchises.
That mix matters because strong revenue durability is most valuable when it also holds up in profitability and cash conversion.
Cash Conversion
Are Eli Lilly and Company’s profits converting into durable cash flow?
Eli Lilly and Company’s margins remain strong, but the latest cash-flow data provided only shows explosive operating cash flow and free cash flow growth, not full dollar amounts. That supports earnings quality directionally, yet durable cash conversion cannot be fully confirmed without complete cash flow statement figures.
At Q1 2026, Eli Lilly and Company reported $1622B gross profit, $885B operating income, and $740B net income on $1980B revenue. Those profit layers matter because gross margin shows product economics, operating margin shows scale after R&D and selling costs, and net margin shows what is left after interest and taxes.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | 81.9% for Q1 2026 | Unavailable in supplied data | $1980B revenue and $358B cost of revenue | Shows strong product economics despite the -7% US realized price change. |
| Operating Margin | 44.7% for Q1 2026 | Unavailable in supplied data | $351B R&D, $293B SG&A, and $737B operating expenses | Shows scale is still absorbing heavy reinvestment and commercialization costs. |
| Net Margin | 37.4% for Q1 2026 | Unavailable in supplied data | $33200M interest expense and $145B income tax expense | Shows final profitability still converts well after financing and tax costs. |
| Operating Cash Flow | Available only as 6538% growth for 2026-03-31 | Unavailable in supplied data | Directional cash-flow growth only; working-capital detail not provided | Suggests cash generation improved sharply, but the dollar base is missing. |
| Free Cash Flow | Available only as 34358% growth for 2026-03-31 | Unavailable in supplied data | Capex dollar value not provided | Shows strong directional improvement, but reinvestment burden cannot be sized. |
What most affects Eli Lilly and Company’s cash conversion?
Pricing pressure is the main test. The -7% US realized price change, plus the low-to-mid teens full-year price headwind, matters because it can limit how much reported profit turns into repeatable cash.
- Main Driver: Pricing pressure looks structural for now, while the reported R&D and SG&A load is a real operating choice.
- Evidence Gap: The supplied data does not include operating cash flow, capital expenditure, or free cash flow dollar amounts.
- Metric to Monitor: Track operating cash flow margin and free cash flow after capex.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. For related ownership context, see Exploring Eli Lilly and Company (LLY) Investor Profile: Who's Buying and Why?
Balance-Sheet Flexibility
Does Eli Lilly and Company have enough balance-sheet flexibility to support its obligations and investment needs?
Balance Sheet and Liquidity are Mixed. Eli Lilly and Company benefits from large earnings scale and capital access, but the main financing concern is incomplete debt-maturity and liquidity detail, especially with acquisition funding demands and a $33200M Q1 2026 interest expense to monitor.
Cash alone is not enough here. A real balance-sheet view should include working capital, asset quality, debt service, solvency, liquidity, and refinancing risk together. The available data for Eli Lilly and Company also fits a broader company review, including Eli Lilly and Company (LLY): History, Ownership, Mission, How It Works & Makes Money.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Enterprise values data for 2026-03-31 shows Minus Cash And Cash Equivalents: $528B; detailed current assets, current liabilities, and liquidity ratios were not supplied. | Mixed | Near-term obligations cannot be fully tested without a complete working-capital view, so investment flexibility is harder to judge. |
| Total and Net Debt | Add Total Debt: $4337B; net debt or net cash cannot be verified from the supplied data alone. | Mixed | Leverage may be manageable or restrictive, but the absence of a full balance sheet keeps that uncertain. |
| Debt Service and Refinancing | Interest Expense: $33200M in Q1 2026; no maturity schedule, coupon detail, or covenant data was supplied. | Mixed | Profit scale helps, but refinancing risk and interest coverage still need direct evidence before comfort is warranted. |
| Asset Quality | FMP Debt Growth: 204%, Receivables Growth: 507%, Inventory Growth: 571%, Asset Growth: 365%, and Book Valueper Share Growth: 1803% on 2026-03-31; these are directional only. | Mixed | Rapid asset and balance-sheet expansion can support growth, but it also raises questions about collection, inventory, and capital intensity. |
| Liabilities and Equity | Latest verified liability and equity totals were not supplied; acquisitions include Centessa Pharmaceuticals for $630B upfront plus $150B in contingent value rights, Orna Therapeutics for $240B, Ventyx Biosciences for $120B, CrossBridge Bio for $300M, Ajax Therapeutics for up to $230B, Vaccine Company for up to $155B in cash and milestones, Curevo Inc for up to $150B in cash and milestones, and LimmaTech Biologics AG for $780M. | Mixed | Acquisitions increase funding needs, so the equity base and liability load matter for how much strategic spending can continue. |
Which balance-sheet risk matters most for Eli Lilly and Company?
Refinancing and acquisition funding risk matters most. The company has scale, but the supplied data do not show maturities, covenants, or net debt, so the safest reading is that liquidity stress would show up first in funding flexibility.
- Current Exposure: Enterprise values data for 2026-03-31 shows Minus Cash And Cash Equivalents: $528B and Add Total Debt: $4337B; full liquidity ratios were not supplied.
- Protection: Large earnings scale and the ability to access capital provide the clearest buffer.
- Warning Signal: Watch debt growth, interest expense, and acquisition funding needs if capital spending stays elevated.
Capital Efficiency
Can Eli Lilly sustain returns while reinvesting heavily?
Mixed. Eli Lilly’s current earnings conversion looks strong, but internal cash may be only partly sufficient because reinvestment needs are still heavy across R&D, manufacturing, AI infrastructure, and acquisitions.
Eli Lilly’s returns should be judged alongside leverage, asset intensity, capital expenditure, working capital, and any external funding need. High returns can still look healthy when a company is adding factories, funding research, and expanding capacity, but the quality of those returns depends on whether cash generation stays ahead of that reinvestment load.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable | No supplied ROIC figure to test directly, but current earnings strength and reinvestment intensity suggest active capital deployment. | Invested capital appears to be supporting operating value, but the return hurdle is high. |
| ROE and ROA | ROE and ROA not supplied; Q1 2026 Net Income: $740B, EPS Diluted: $826, and company-reported EPS Growth: 170% | ROE can be boosted by leverage, while ROA reflects how well assets are used; the supplied earnings data shows strong profit conversion, not a full efficiency test. | Shareholder returns look strong on earnings momentum, but asset efficiency cannot be confirmed from the supplied data alone. |
| Maintenance and Growth Investment | Research And Development Expenses: $351B in FMP; Q1 2026 R&D Expenses: $284B; R&D Growth: 28%; 42 active Phase 3 programs; LillyPod with 16 Nvidia Blackwell Ultra GPUs and 9,000 petaflops; AI-powered factory initiative; tirzepatide capacity expansion; India manufacturing and innovation hub expansion; Ascidian Therapeutics $190B deal; Profluent Bio $225B deal | R&D, manufacturing, AI infrastructure, and acquisitions all point to heavy reinvestment, with limited evidence to separate maintenance from growth spending. | Capital needs appear large and ongoing, which can lift future growth but also pressure near-term returns. |
| Internal Funding Capacity | Weighted Average Shares Outstanding: 89450M; Weighted Average Diluted Shares Outstanding: 89590M for 2026-03-31; Weighted Average Shares Growth: -039%; Weighted Average Shares Diluted Growth: -023% | Share counts suggest limited dilution pressure, but the supplied data do not fully show operating cash flow, free cash flow, cash reserves, or debt. | Investment appears partly internally funded, with the remaining burden not fully verifiable from the supplied figures. |
Are Eli Lilly's returns on capital sustainable?
Probably, because strong earnings conversion and pipeline breadth support durability, but returns could weaken if R&D, AI, manufacturing, and acquisition spending rise faster than cash generation.
- Operating Source: Strong earnings conversion, supported by EPS Diluted: $826 and company-reported EPS Growth: 170%.
- Funding Requirement: The largest verified capital need is sustained R&D, plus manufacturing capacity and AI infrastructure.
- Durability Test: Watch whether R&D intensity and capital spending rise faster than cash conversion, which would pressure ROIC and ROA.
If you’re using this topic for a paper or case study, a structured SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments. For a broader view of strategy and governance, see Mission Statement, Vision, & Core Values (2026) of Eli Lilly and Company (LLY).
Pricing Pressure
How resilient is Eli Lilly and Company, and which warning signs matter most?
Resilience is Mixed. The main buffer is Eli Lilly and Company’s large revenue base and strong operating momentum. The most important verified warning sign is pricing pressure, with a low-to-mid teens percentage Realized Price Headwind for full-year 2026 and -7% US Realized Price Change.
Eli Lilly and Company can still fund core investment because scale, Q1 2026 Net Income of $740B, and Updated Full-Year 2026 Revenue Guidance of $8200B–$8500B support cash generation. Still, investors should watch whether pricing, R&D, manufacturing expansion, and acquisitions absorb too much cash, especially if access or legal issues start to affect collections.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Lower realized pricing can reduce operating leverage, slow earnings growth, and weaken cash flow even if volume stays strong. That can also limit debt capacity over time. | Volume growth and full-year guidance can offset some price pressure, and Eli Lilly and Company still has broad scale. | A further decline in realized price change or a smaller-than-expected margin trend would confirm deterioration. |
| Working-Capital or Investment Pressure | Research and development, manufacturing expansion, AI infrastructure, and acquisitions can absorb cash and raise reinvestment needs. Research And Development Expenses of $351B and Q1 2026 R&D Expenses of $284B show the scale of spending, with R&D Growth of 28%. | Large revenue scale and Q1 2026 Net Income of $740B help fund investment internally. | Weak operating cash flow, faster asset growth, or sustained R&D acceleration without matching sales would be the key signal. |
| Interest or Refinancing Pressure | Cash and debt need close monitoring because 2026-03-31 data shows Minus Cash And Cash Equivalents of $528B and Add Total Debt of $4337B. Higher leverage can reduce financing flexibility if conditions tighten. | Strong current earnings and access to ongoing operating cash flow help support obligations. | Rising debt, weaker liquidity, or higher interest burden would show increasing pressure. |
Which financial warning signs should investors monitor at Eli Lilly and Company?
The strongest signals are realized price change, cash flow versus reinvestment, and liquidity/debt. The pricing issue is already confirmed by guidance; legal and access risks, acquisition execution, and funding strain are future risks to track closely.
Realized price pressure is the clearest near-term risk
Evidence points to a low-to-mid teens percentage Realized Price Headwind and -7% US Realized Price Change. Volume growth can offset this, but investors should watch for further weakening in pricing because it would pressure earnings quality.
Reinvestment demands could absorb more cash
R&D, manufacturing expansion, AI infrastructure, and multiple acquisitions all require funding. Eli Lilly and Company can support this with scale and Q1 2026 Net Income of $740B, but slower operating cash flow would raise pressure.
Legal and access uncertainty can hit pricing and cash flow
Active compounded tirzepatide litigation, the Texas Attorney General kickback lawsuit with final resolution pending, and Medicare discount and bridge program changes could affect reimbursement, pricing, or collections. Monitor whether these issues start to change access or cash flow.
Financial Health Scorecard
What does Eli Lilly and Company’s financial health mean for investors?
Overall rating: Mixed. The strongest factor is Revenue and Earnings Quality, while the weakest is Balance Sheet and Liquidity visibility. The most important condition for the investment case is whether earnings growth can keep outrunning pricing pressure and heavy reinvestment.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | $1980B revenue, 56% growth, $740B net income, and 170% EPS growth show strong demand and good per-share conversion. |
| Profitability and Cash | Strong | $885B operating income and sharp cash-flow growth point to powerful profit momentum, though no operating cash flow or free cash flow dollar value is supplied. |
| Balance Sheet and Liquidity | Mixed | Enterprise value data shows -$528B cash and cash equivalents and $4337B debt, but no full balance sheet, maturity schedule, or coverage ratios are provided. |
| Capital Efficiency | Mixed | Earnings are strong, but R&D, AI infrastructure, manufacturing expansion, and acquisitions likely require continued high returns to justify reinvestment. |
| Financial Resilience | Mixed | -7% US realized price change, legal disputes, and reinvestment intensity create pressure, even with strong operating scale and earnings momentum. |
- What Supports the Thesis: Strong revenue growth, rising EPS, and powerful profit conversion give Eli Lilly and Company a clear operating base.
- What Challenges the Thesis: Pricing pressure, legal disputes, and heavy reinvestment make future cash durability less certain.
- What to Monitor: Revenue growth, diluted EPS, realized price change.
For investors using Exploring Eli Lilly and Company (LLY) Investor Profile: Who's Buying and Why?, the key question is whether these trends hold up in forecasts, scenarios, and valuation assumptions.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
What does Lilly’s negative realized price change mean?
It means average realized US pricing moved lower, with US Realized Price Change: -7% For financial health, the issue is whether higher prescription volume, product mix, and scale can offset price pressure without weakening profit growth or cash conversion
Can Lilly fund growth without adding more debt?
The provided data does not prove that Lilly can fund all growth without more debt Q1 2026 earnings are strong, but Enterprise Values data shows $528B of cash and cash equivalents and $4337B of total debt, while major acquisitions and manufacturing expansion increase funding needs
Does heavy R&D spending lower capital efficiency?
Heavy R&D can lower capital efficiency if projects fail to create future revenue and earnings For Lilly, R&D is also a growth engine, supported by 42 active Phase 3 programs, but investors should compare R&D spending with future approvals, revenue growth, EPS, and cash conversion
How should investors read Lilly’s revenue guidance?
Updated Full-Year 2026 Revenue Guidance of $8200B–$8500B supports visibility for the current year Investors should treat it as a planning range, not a guarantee, and compare future quarters against revenue growth, diluted EPS, and realized price change
Why is liquidity visibility mixed for Lilly?
Liquidity visibility is mixed because the data provides cash, debt, earnings, and growth indicators, but not full Balance Sheet, maturity, working capital, coverage, or Cash Flow statement values That limits conclusions about refinancing risk, cash reserves, and free cash flow capacity